JPRN-jRCT2080221467未知1 期
Phase 1b study of U3-1287 in combination with erlotinib in subjects with advanced non-small cell lung cancer (NSCLC)
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 36 人开始时间: 2011年5月31日最近更新:
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Histologically or cytologically diagnosed advanced NSCLC has progressed on at least one prior chemotherapy
- •-Stage IIIB or IV disease
- •-Measurable tumour lesions and malignant lymph nodes per RECIST ver 1.1
- •-ECOG performance status: 0-1
排除标准
- •-Has history of erlotinib or anti-HER3 therapy
- •-Patients with active other malignancies
- •-History of any of the following diseases or comorbid medical conditions: interstitial lung disease, heart failure, myocardial infarction, cerebral infarction, active angina, arrhythmia requiring medication, coronary/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thrombosis, deep vein thrombosis, other clinically significant thromboembolic events, diverticulitis, or clinically significant pulmonary disease (e.g., lung infection, COPD, or asthma)
- •-Patients with any severe or uncontrolled comorbid medical conditions in spite of medications
- •-Has brain metastasis with clinical symptoms or requiring treatment
- •-Has history of bleeding diathesis (e.g., hemoptysis)
- •-Has history of serious drug hypersensitivity such as anaphylactoid reaction
研究者
相似试验
未知
1 期
Phase 1b study of U3-1287 in combination with trastuzumab plus paclitaxel in patients with HER2-positive metastatic breast cancer (MBC)HER2-positive MBCJPRN-jRCT2080221730DAIICHISANKYO Co.,Ltd.36
已完成
1 期
A Phase I study of patients with advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancerPatients with epithelial ovarian, primary peritoneal, or fallopian tube cancerJPRN-jRCT2080223109Taiho Pharmaceutical Co., Ltd.30
招募中
3 期
A phase 3 study of S-812217 in combination with an antidepressant in patients with major depressive disorderdepressionJPRN-jRCT2031220423Gomez Juan Carlos100
进行中（未招募）
1 期
Clinical evaluation of virus therapy for malignant melanomaMalignant melanomaMedDRA version: 20.0Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 100000004858EUCTR2019-003300-12-SEokon Pharma AB50
进行中（未招募）
不适用
Estudio en fase 3 de SU011248 en combinación con paclitaxel versus bevacizumab con paclitaxel como tratamiento de primera linea en pacientes con cáncer de mama avanzado. A phase 3 study of SU011248 in combination with paclitaxel versus bevacizumab with paclitaxel in the first-line advanced disease setting in patients having breast cancer.Cáncer de mama localmente recurrente o metastásicoLocally recurrent or metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10006198Term: Breast cancer recurrentMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-002969-12-ESPfizer, S.A.740